Introduction:

Aortic stenosis and regurgitation have a prevalence of six percent among patients over 65 years old, in Mexico represents half a million people at risk. The most use procedure to treat these diseases is surgical aortic valve replacement SAVR. Patients with low ejection fraction ≤ 35% that require replacement of the valve, have an increase in perioperative morbidity and mortality, there are few clinical trials which report their clinical outcomes in Mexico.

Material and methods:

We conducted a retrospective, transverse, observational, not randomize trial, in patients with diagnosis of aortic stenosis and/or regurgitation and reduce ejection fraction of the left ventricle ≤ 35%, who underwent SAVR between October 1 of 2017 and June 30 of 2018; we evaluate demographics, surgical outcomes, mortality and morbidity.

Results:

We found 14 patients with a mean LVEF of 26.85% (SD 7.16). Diagnosis of: stenosis and regurgitation in seven patients (50%), pure stenosis in five patients (36%) and regurgitation alone in two patients (14%); five were urgencies (35.7%); the mean bleeding was 301 cc (SD 446.6), 7% presented atrioventricular block, 30 days mortality at 7.1%.

Conclusions:

Except for hospital stay, the morbidity and mortality are similar to the data reported by other trials.